A clinical case of treatment of a patient with acute adrenal insufficiency after combined immunotherapy (nivolumab + ipilimumab). Prospects for a return to immunotherapy after severe complications of immunotherapy

Checkpoint inhibitors, as well as their combinations, are increasingly included in the daily practice of the oncologist. However, given the mechanism of action, its use may be associated with immune side effects that can complicate the clinical course and prognosis of patients. As the number of reported indications for the administration of PD-1, PD-L1, CTLA-4 inhibitors increases, the rate of reports of rare complications associated with immunotherapy increases. Among the complications, it is worth highlighting the group of autoimmune endocrinopathies. Such complications of immunotherapy as hypophysitis, hypo- and hyperthyroidism are quite common, are relatively easy to correct and usually do not lead to discontinuation of therapy. The mechanisms underlying immune damage to target organs remain poorly understood. Primary adrenal insufficiency is a rare and potentially life-threatening complication that, due to non-specific symptoms, may be recognized too late. The development of adrenal insufficiency was noted in only 0.7% of patients in randomized clinical trials. To date, there is no single tactic for identifying and treating this complication. The management of such patients is possible only by a multidisciplinary team that includes an endocrinologist. We present a clinical case of the development of adrenal insufficiency on the background of combined chemo-immunotherapy and the results of the patient’s treatment after its resolution. 

1. Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173–182. doi: 10.1001/jamaoncol.2017.3064.

2. Neril R., Lorton J., Zonszein J. Nivolumab-Induced Isolated Adrenal Insufficiency: A Case Report. AACE Clin Case Rep. 2017;3(3):e210–e212. doi: 10.4158/EP161491.CR.

3. Oristrell G., Bañeras J., Ros J., Muñoz E. Cardiac Tamponade and Adrenal Insufficiency Due to Pembrolizumab: A Case Report. Eur Heart J Case Rep. 2018;2(2):yty038. doi: 10.1093/ehjcr/yty038.

4. Sakaguchi C., Yano S., Ashida K., Wada N., Ohe K., Nagata H. et al. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. Am J Case Rep. 2019;20:106–110. doi: 10.12659/AJCR.913021.

5. Sznol M., Postow M.A., Davies M.J., Pavlick A.C., Plimack E.R., Shaheen M. et al. Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treat Rev. 2017;58:70–76. doi: 10.1016/j.ctrv.2017.06.002.

6. Win M.A., Thein K.Z., Qdaisat A., Yeung S.J. Acute Symptomatic Hypocalcemia from Immune Checkpoint Therapy-Induced Hypoparathyroidism. Am J Emerg Med. 2017;35(7):1039.e5–1039.e7. doi: 10.1016/j.ajem.2017.02.048.

7. Illouz F., Briet C., Cloix L., Le Corre Y., Baize N., Urban T. et al. Endocrine Toxicity of Immune Checkpoint Inhibitors: Essential Crosstalk between Endocrinologists and Oncologists. Cancer Med. 2017;6(8):1923–1929. doi: 10.1002/cam4.1145.

8. Iglesias P. Cancer Immunotherapy-Induced Endocrinopathies: Clinical Behavior and Therapeutic Approach. Eur J Intern Med. 2018;47:6–13. doi: 10.1016/j.ejim.2017.08.019.

9. Weber J.S., Dummer R., de Pril V., Lebbé C., Hodi F.S. Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest with Ipilimumab: Detailed Safety Analysis from a Phase 3 Trial in Patients with Advanced Melanoma. Cancer. 2013;119(9):1675–1682. doi: 10.1002/ cncr.27969.

10. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/ NEJMoa1504030.

11. Doroshow D.B., Sanmamed M.F., Hastings K., Politi K., Rimm D.L., Chen L. et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi: 10.1158/1078-0432.CCR-181538.

12. Paz-Ares L., Ciuleanu T.-E., Cobo M., Schenker M., Zurawski B., Menezes J. et al. First-Line Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2021;22(2):198–211. doi: 10.1016/S1470-2045(20)30641-0.

13. Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y. et al. Spectrum of Immune Checkpoint Inhibitors-Induced Endocrinopathies in Cancer Patients: A Scoping Review of Case Reports. Clin Diabetes Endocrinol. 2019;5:1. doi: 10.1186/s40842-018-0073-4.

14. Nogueira E., Newsom-Davis T., Morganstein D.L. Immunotherapy-Induced Endocrinol Metab. 2019;10:2042018819896182. doi: 10.1177/2042018819896182.

15. Brahmer J.R., Lacchetti C., Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M. et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. doi: 10.1200/JCO.2017.77.6385.

16. Haanen J.B.A.G., Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol. 2017;28(suppl_4):iv119–iv142. doi: 10.1093/annonc/ mdx225.

17. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R., Topalian S.L. et al. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated with Enteritis and Hypophysitis. J Immunother. 2007;30:825–830. doi: 10.1097/cji.0b013e318156e47e.

18. Min L., Ibrahim N. Ipilimumab-Induced Autoimmune Adrenalitis. Lancet Diabetes Endocrinol. 2013;1(3):e15. doi: 10.1016/S2213-8587(13)70031-7 .

19. Paepegaey A.C., Lheure C., Ratour C., Lethielleux G., Clerc J., Bertherat J. et al. Polyendocrinopathy Resulting from Pembrolizumab in a Patient with a Malignant Melanoma. J Endocr Soc. 2017;1:646–649. doi: 10.1210/js.201700170.

20. Trainer H., Hulse P., Higham C.E., Trainer P., Lorigan P. Hyponatraemia Secondary to Nivolumab-Induced Primary Adrenal Failure. Endocrinol Diabetes Metab Case Rep. 2016:16–0108. doi: 10.1530/EDM16-0106.

21. Akarca F.K., Can O., Yalcinli S., Altunci Y.A. Nivolumab, A New Immunomodulatory Drug, A New Adverse Effect; Adrenal Crisis. Turk J Emerg Med. 2017;17(4):157–159. doi: 10.1016/j.tjem.2017.05.007